PHK
ANIK icon

Point72 Hong Kong’s Anika Therapeutics ANIK Stock Holding History

Point72 Hong Kong’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,096
Closed -$39K – 1813
2021
Q4 		$39K Buy
+1,096
New +$43.9K ﹤0.01% 1394
2020
Q1 		– Sell
-242
Closed -$13K – 933
2019
Q4 		$13K Buy
242
+143
+144% +$8.31K ﹤0.01% 954
2019
Q3 		$5K Buy
+99
New +$5.08K ﹤0.01% 805

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Point72 Hong Kong's ANIK Position: Q1 2022 in Review

Point72 Hong Kong sold out of Anika Therapeutics (ANIK) in Q1 2022, closing a stake of 1,096 shares — an estimated $39K sold.

Point72 Hong Kong first reported a position in ANIK in Q3 2019 and held it in 3 quarters. The position peaked at $39K in Q4 2021. 118 funds tracked by Wall St. Rank hold ANIK as of Q1 2022.

  • Point72 Hong Kong reported no remaining Anika Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 1,096 Anika Therapeutics shares in Q1 2022, an estimated $39K.
  • Point72 Hong Kong first reported a position in Anika Therapeutics in Q3 2019 and held it in 3 quarters.
  • Point72 Hong Kong's Anika Therapeutics position peaked at $39K in Q4 2021.
  • 118 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2022.

Based on Point72 Hong Kong's 13F filing for Q1 2022, filed 16 May 2022.